Last update June 12, 2020
Soluble fusion protein used for treatment of Rheumatoid Arthritis and other autoimmune diseases.
Abatacept is a biological disease-modifying antirheumatic drug (DMARD).
Weekly administration subcutaneously.
Its very high molecular weight probably explain the negligible excretion observed in milk (Saito 2019). No health or immunization problems have been observed in an infant breastfed by a mother treated with abatacept (Saito 2019).
Its nil oral bioavailability would make it difficult its passage to the infant’s plasma through breast milk except in premature babies and in the immediate neonatal period during which there may be greater intestinal permeability.
Several medical societies, experts and expert consensus, consider the use of this medication to be compatible or very probably compatible during breastfeeding if no other options are available (Sammaritano 2020, Hale 2019, Götestam 2016).
Suggestions made at e-lactancia are done by APILAM team of health professionals, and are based on updated scientific publications. It is not intended to replace the relationship you have with your doctor but to compound it. The pharmaceutical industry contraindicates breastfeeding, mistakenly and without scientific reasons, in most of the drug data sheets.
Your contribution is essential for this service to continue to exist. We need the generosity of people like you who believe in the benefits of breastfeeding.
Thank you for helping to protect and promote breastfeeding.
e-lactancia is a resource recommended by Academy of Breastfeeding Medicine - 2012 of United States of America
Would you like to recommend the use of e-lactancia? Write to us at corporate mail of APILAM